Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin.

Article Details

Citation

Copy to clipboard

Rey E, Rivard GE

Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin.

Int J Gynaecol Obstet. 2000 Oct;71(1):19-24.

PubMed ID

11044537 [ View in PubMed

]

Abstract

OBJECTIVES: To determine if a prophylactic dose of dalteparin, 5000 IU daily, and if the adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily are appropriate in pregnancy. METHOD: Anti-Xa activity levels were used to assess prophylactic (33 women) and therapeutic (15 women) dalteparin dosage throughout pregnancy. Analysis of variance was used and P-values less than 0.05 were considered statistically significant. RESULTS: In the prophylactic group, anti-Xa activity levels did not vary significantly throughout pregnancy (P=0.15). The initial dalteparin dose was modified on the first anti-Xa activity measurement in eight women, whose weight was statistically different from those remaining on the initial dose (P<0.001). The adjusted-weight therapeutic dalteparin dose induced adequate anti-Xa activity levels. CONCLUSIONS: Dalteparin, 5000 IU daily, is suitable for most pregnant women and does not need to be modified in the third trimester. A therapeutic dalteparin dose adjusted according to pregnancy weight is appropriate.

DrugBank Data that Cites this Article

Drugs

Dalteparin

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Dalteparin	Antithrombin-III	Protein	Humans	Yes	Potentiator	Details
Dalteparin	P-selectin	Protein	Humans	Unknown	Inhibitor	Details